查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1751198

生長抑制素類似物市場規模、佔有率、趨勢分析報告：按類型、應用、最終用途、地區、細分市場預測，2025-2030

Somatostatin Analogs Market Size, Share & Trends Analysis Report By Type (Octreotide, Lanreotide, Pasireotide), By Application (Acromegaly, NET), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

生長抑制素類似物市場的成長與趨勢：

根據 Grand View Research 的新報告，全球生長抑制素類似物市場規模預計到 2030 年將達到 111 億美元，2025 年至 2030 年的複合年成長率為 13.3%。

提高對肢端肥大症和神經內分泌腫瘤等疾病的認知有望成為產生影響的關鍵促進因素。

肢端肥大症是一種慢性內分泌疾病，由生長激素分泌過多引起，通常由腦下垂體腺瘤引起。據估計，到2023年，全球每百萬人中約有4600人患有肢端肥大症，每年每百萬人中診斷出116.9例新病例，且這一數字還在持續上升。此病通常在男性40歲左右、女性45歲左右確診，但通常在三歲時開始發病。因此，肢端肥大症盛行率的上升正在推動生長抑制素類似物市場的發展。

韓國、日本和印度等國家神經內分泌癌（NET）診斷率的上升和人均收入的提高是市場的主要驅動力。此外，製藥公司不斷增加的投資預計也將創造豐厚的成長機會。各種提供各種疾病相關資訊的線上入口網站的出現，預計將提高人們的認知度。例如，神經內分泌癌認知網路 (NIOEN) 提供與症狀、可用治療方案和疾病管理相關的所有資訊。

生長抑制素類似物市場亮點

  • 根據類型，Octreotide在生長抑制素類似物市場佔據主導地位，2024 年的銷售佔有率為 36.3%。
  • 預計在預測期內，Pasireotide部分將以最快的複合年成長率成長。
  • 根據應用，NETs 部門預計將在 2024 年佔據最大的收益佔有率，主導生長抑制素類似物市場，並在預測期內以最快的複合年成長率成長。
  • 醫院是生長抑制素類似物市場的主導者，在 2024 年佔據最大的收益佔有率。
  • 2024 年，醫院將佔據市場主導地位，而診所領域預計將以最快的速度成長，預測期內複合年成長率為 14.4%。
  • 由於該地區主要參與者的存在，北美佔據了全球市場的主導地位。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章生長抑制素類似物市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章生長抑制素類似物市場：按類型分類的商業分析

  • 2024 年及 2030 年各類型市場佔有率
  • 類型細分細分儀表板
  • 按類型分類的市場規模、預測和趨勢分析（2018-2030 年）
  • Octreotide
  • Lanreotide
  • Pasireotide
  • 其他

第5章生長抑制素類似物市場：按應用進行的業務分析

  • 2024 年及 2030 年各應用領域的市場佔有率
  • 應用程式細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2018-2030 年）
  • 肢端肥大症
  • NET
  • 其他

第6章生長抑制素類似物市場：依最終用途進行的商業分析

  • 2024 年和 2030 年按最終用途分類的市場佔有率
  • 最終用途細分儀表板
  • 按最終用途分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院
  • 診所
  • 其他

第7章生長抑制素類似物市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 市場規模、預測趨勢分析，2018 年至 2030 年：
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年各國情況
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
    • 俄羅斯
  • 亞太地區
    • 2018-2030年各國情況
    • 印度
    • 中國
    • 韓國
    • 香港
    • 澳洲
    • 新加坡
    • 日本
    • 泰國
  • 拉丁美洲
    • 2018-2030年各國情況
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030年各國情況
    • 科威特
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國

第8章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/列表
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Eli Lilly and Company
    • Medical Device Business Services, Inc.
    • Johnson &Johnson Services, Inc.
    • Stryker
    • Ultragenyx Pharmaceutical Inc.
    • Alexion Pharmaceuticals, Inc.
Product Code: GVR-3-68038-789-6

Somatostatin Analogs Market Growth & Trends:

The global somatostatin analogs market size is anticipated to reach USD 11.1 billion by 2030 and expand at a CAGR of 13.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing awareness of diseases such as acromegaly and neuroendocrine tumors is expected to be the vital impact rendering driver.

Acromegaly is a chronic endocrine condition caused by excessive growth hormone production, often due to a pituitary adenoma. In 2023, approximately 4,600 people per million globally were affected by acromegaly, with an estimated 116.9 new cases diagnosed annually per million, a number that continues to rise. The disorder is usually diagnosed around age 40 in men and 45 in women, though it often begins in the third decade of life. Hence, the increasing prevalence of acromegaly drives the somatostatin analogs market.

The growing rate of NET diagnoses in countries such as South Korea, Japan, and India and increasing per capita income are significant market drivers. In addition, rising investments from pharmaceutical companies are expected to create lucrative growth opportunities. Existence of different online portals providing related information on various diseases is anticipated to create awareness among the population. For instance, Neuroendocrine Cancer Awareness Network provides all the information related to their symptoms, available treatment options and disease management.

Somatostatin Analogs Market Highlights

  • By type, octreotide dominated the somatostatin analogs market, with a revenue share of 36.3% in 2024.
  • The pasireotide segment is expected to grow at the fastest CAGR over the forecast period.
  • By application, the NET segment dominated the somatostatin analogs market with the largest revenue share in 2024 and is expected to grow at the fastest CAGR over the forecast period.
  • Hospitals led the somatostatin analogs market, accounting for the largest revenue share in 2024.
  • Hospitals dominated the market in 2024, and the clinics segment is expected to grow at the fastest CAGR of 14.4% over the forecast period.
  • North America dominated the global market owing to the presence of key players in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Somatostatin Analogs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Somatostatin Analogs Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Octreotide
    • 4.4.1. Octreotide Market, 2018 - 2030 (USD Million)
  • 4.5. Lanreotide
    • 4.5.1. Lanreotide Market, 2018 - 2030 (USD Million)
  • 4.6. Pasireotide
    • 4.6.1. Pasireotide Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 5. Somatostatin Analogs Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Acromegaly
    • 5.4.1. Somatostatin Analogs Market, in Acromegaly, 2018 - 2030 (USD Million)
  • 5.5. NET
    • 5.5.1. Somatostatin Analogs Market, in NET, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Somatostatin Analogs Market, in Others, 2018 - 2030 (USD Million)

Chapter 6. Somatostatin Analogs Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Segment Market, 2018 - 2030 (USD Million)
  • 6.5. Clinics
    • 6.5.1. Clinics Segment Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Segment Market, 2018 - 2030 (USD Million)

Chapter 7. Somatostatin Analogs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.10. Russia
      • 7.5.10.1. Key Country Dynamics
      • 7.5.10.2. Regulatory Framework
      • 7.5.10.3. Competitive Insights
      • 7.5.10.4. Russia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. India Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. South Korea Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Hong Kong
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Hong Kong Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Singapore
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Singapore Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.8. Japan
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Regulatory Framework
      • 7.6.8.3. Competitive Insights
      • 7.6.8.4. Japan Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.9. Thailand
      • 7.6.9.1. Key Country Dynamics
      • 7.6.9.2. Regulatory Framework
      • 7.6.9.3. Competitive Insights
      • 7.6.9.4. Thailand Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. Middle East & Africa Somatostatin Analogs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. Kuwait
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. Kuwait Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. South Africa
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. South Africa Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. UAE
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. UAE Somatostatin Analogs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Novo Nordisk A/S
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Type Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Type Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eli Lilly and Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Type Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Medical Device Business Services, Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Type Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Johnson & Johnson Services, Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Type Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Stryker
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Type Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Ultragenyx Pharmaceutical Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Type Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Alexion Pharmaceuticals, Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Type Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global somatostatin analogs market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 5. Global somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 6. Global somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 7. North America somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 9. North America somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 10. North America somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 11. U.S. somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 12. U.S. somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 13. U.S. somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 14. Canada somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 15. Canada somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 16. Canada somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 17. Mexico somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 18. Mexico somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 19. Mexico somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 20. Europe somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 22. Europe somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 23. Europe somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 24. UK somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 25. UK somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 26. UK somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 27. Germany somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 28. Germany somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 29. Germany somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 30. France somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 31. France somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 32. France somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 33. Italy somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 34. Italy somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 35. Italy somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 36. Spain somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 37. Spain somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 38. Spain somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 39. Denmark somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 40. Denmark somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 41. Denmark somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 42. Sweden somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 43. Sweden somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 44. Sweden somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 45. Norway somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 46. Norway somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 47. Norway somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 48. Russia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 49. Russia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 50. Russia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 52. Asia Pacific somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 53. Asia Pacific somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 54. Asia Pacific somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 55. India somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 56. India somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 57. India somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 58. China somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 59. China somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 60. China somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 61. South Korea somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 62. South Korea somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 63. South Korea somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 64. Hong Kong somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 65. Hong Kong somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 66. Hong Kong somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 67. Australia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 68. Australia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 69. Australia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 70. Singapore somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 71. Singapore somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 72. Singapore somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 73. Japan somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 74. Japan somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 75. Japan somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 76. Thailand somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 77. Thailand somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 78. Thailand somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 79. Latin America somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 80. Latin America somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 81. Latin America somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 82. Latin America somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 83. Brazil somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 84. Brazil somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 85. Brazil somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 86. Argentina somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 87. Argentina somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 88. Argentina somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 89. Middle East & Africa somatostatin analogs market, by country, 2018 - 2030 (USD Million)
  • Table 90. Middle East & Africa somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 91. Middle East & Africa somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 92. Middle East & Africa somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 93. Kuwait somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 94. Kuwait somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 95. Kuwait somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 96. Saudi Arabia somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 97. Saudi Arabia somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 98. Saudi Arabia somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 99. South Africa somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 100. South Africa somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 101. South Africa somatostatin analogs market, by end use, 2018 - 2030 (USD Million)
  • Table 102. UAE somatostatin analogs market, by type, 2018 - 2030 (USD Million)
  • Table 103. UAE somatostatin analogs market, by application, 2018 - 2030 (USD Million)
  • Table 104. UAE somatostatin analogs market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Somatostatin analogs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type outlook (USD Million)
  • Fig. 10 Application outlook (USD Million)
  • Fig. 11 End Use outlook (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 Somatostatin analogs market dynamics
  • Fig. 14 Somatostatin analogs market: Porter's five forces analysis
  • Fig. 15 Somatostatin analogs market: Pestle analysis
  • Fig. 16 Somatostatin analogs market: Type segment dashboard
  • Fig. 17 Somatostatin analogs market: Type market share analysis, 2024 & 2030
  • Fig. 18 Octreotide market, 2018 - 2030 (USD Million)
  • Fig. 19 Lanreotide market, 2018 - 2030 (USD Million)
  • Fig. 20 Pasireotide market, 2018 - 2030 (USD Million)
  • Fig. 21 Others market, 2018 - 2030 (USD Million)
  • Fig. 22 Somatostatin analogs market: Application segment dashboard
  • Fig. 23 Somatostatin analogs market: Application market share analysis, 2024 & 2030
  • Fig. 24 Somatostatin analogs market, in Acromegaly, 2018 - 2030 (USD Million)
  • Fig. 25 Somatostatin analogs market, in NET, 2018 - 2030 (USD Million)
  • Fig. 26 Somatostatin analogs market, in Others, 2018 - 2030 (USD Million)
  • Fig. 27 Somatostatin analogs market: End Use segment dashboard
  • Fig. 28 Somatostatin analogs market: End Use market share analysis, 2024 & 2030
  • Fig. 29 Hospitals segment market, 2018 - 2030 (USD Million)
  • Fig. 30 Clinics segment market, 2018 - 2030 (USD Million)
  • Fig. 31 Others segment market, 2018 - 2030 (USD Million)
  • Fig. 32 Somatostatin analogs market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 57 Norway country dynamics
  • Fig. 58 Norway somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 59 Russia country dynamics
  • Fig. 60 Russia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 64 China country dynamics
  • Fig. 65 China somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 68 Hong Kong country dynamics
  • Fig. 69 Hong Kong somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 70 Australia country dynamics
  • Fig. 71 Australia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 72 Singapore country dynamics
  • Fig. 73 Singapore somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 74 Japan country dynamics
  • Fig. 75 Japan somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 76 Thailand country dynamics
  • Fig. 77 Thailand somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil country dynamics
  • Fig. 80 Brazil somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina country dynamics
  • Fig. 82 Argentina somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East & Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa country dynamics
  • Fig. 85 South Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait country dynamics
  • Fig. 87 Kuwait somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia country dynamics
  • Fig. 89 Saudi Arabia somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 90 South Africa country dynamics
  • Fig. 91 South Africa somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 92 UAE country dynamics
  • Fig. 93 UAE somatostatin analogs market, 2018 - 2030 (USD Million)
  • Fig. 94 Company categorization
  • Fig. 95 Company market position analysis
  • Fig. 96 Strategic framework